Weekly shot shows promise for diabetes control in major trial
NCT ID NCT06258148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new weekly injection called TG103 in 465 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either a low dose, a higher dose, or a placebo for several weeks. The main goal was to see if TG103 could lower blood sugar levels (measured by HbA1c) and help with weight loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- Fig leaf tea may shield kidneys from diabetes damage — a trial puts it to the test
- Can a nasal spray of insulin shield the aging brain from Post-Surgery confusion?
- Smartphone app could improve blood sugar control in type 2 diabetes
- Personalizing kidney treatment: can biomarkers predict who benefits from finerenone?
- Diabetes drug class may change how the bladder behaves